LRRK2 G2019S mutation does not contribute to Parkinson′s disease in South India

Neurology India

Volumn 59, Issue 2, 2011, Pages 157-160

  Vijayan, Bejoy ^a   Gopala, Srinivas ^a   Kishore, Asha ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

G2019S mutation; India; LRRK2; Parkinson s disease

Indexed keywords

DNA; LEUCINE RICH REPEAT KINASE 2;

ADULT; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ETHNICITY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE;

AGED; ALLELES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 79955432541     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.79125     Document Type: Article

References (30)

1. Paisan-Ruiz C. LRRK2 gene variation and its contribution to Parkinson disease. Hum Mutat 2009;30:1153-60.
2. Biskup S, West AB. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 2009;1792:625-33.
3. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-90.
4. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-80. (Pubitemid 40432174)
5. Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006;67:1786-91. (Pubitemid 44900754)
6. Goldwurm S, Di Fonzo A, Simons EJ, Rohé CF, Zini M, Canesi M, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 2005;42:e65.
7. Bar-Shira A, Hutter CM, Giladi N, Zabetian CP, Orr-Urtreger A. Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. Neurogenetics 2009;10:355-8.
8. Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 2006;79:752-8. (Pubitemid 44452754)
9. Vinish M, Prabhakar S, Khullar M, Verma I, Anand A. Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for Parkinsonism in North West India. J Neurol Neurosurg Psychiatry 2010;81:166-70.
10. Chaudhary S, Behari M, Dihana M, Swaminath PV, Govindappa ST, Jayaram S, et al. Parkin mutations in familial and sporadic Parkinson's disease among Indians. Parkinsonism Relat Disord 2006;12:239-45. (Pubitemid 43737242)
11. Madegowda RH, Kishore A, Anand A. Mutational screening of the parkin gene among South Indians with early onset Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:1588-90. (Pubitemid 41531714)
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
13. Bras JM, Guerreiro RJ, Ribeiro MH, Januario C, Morgadinho A, Oliveira CR, et al. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov Disord 2005;20:1653-5.
14. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, New Jersey: Humana Press; 2000. p. 365-86.
15. Punia S, Behari M, Govindappa ST, Swaminath PV, Jayaram S, Goyal V, et al. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. Neurosci Lett 2006;409:83-8. (Pubitemid 44637251)
16. Zabetian CP, Morino H, Ujike H, Yamamoto M, Oda M, Maruyama H, et al. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 2006;67:697-9. (Pubitemid 44273625)
17. Papapetropoulos S, Adi N, Shehadeh L, Bishopric N, Singer C, Argyriou AA, et al. Is the G2019S LRRK2 mutation common in all southern European populations? J Clin Neurosci 2008;15:1027-30.
18. Shojaee S, Sina F, Farboodi N, Fazlali Z, Ghazavi F, Ghorashi SA, et al. A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson's disease patients. Mov Disord 2009;24:1023-7.
19. Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Dürr A, et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 2005;77:330-2. (Pubitemid 41022715)
20. Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, et al. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord 2008;14:77-80.
21. Mata IF, Cosentino C, Marca V, Torres L, Mazzetti P, Ortega O, et al. LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism Relat Disord 2009;15:370-3.
22. Huang Y, Halliday GM, Vandebona H, Mellick GD, Mastaglia F, Stevens J, et al. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord 2007;22:982-9. (Pubitemid 46999295)
23. Benamer HT. The ancestry of LRRK2 Gly2019Ser Parkinsonism. Lancet Neurol 2008;7:769-70.
24. Pirkevi C, Lesage S, Condroyer C, Tomiyama H, Hattori N, Ertan S, et al. A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype. Neurogenetics 2009;10:271-3.
25. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 2005;384:327-9. (Pubitemid 40836023)
26. Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 2006;21:1102-8. (Pubitemid 44336593)
27. Cho JW, Kim SY, Park SS, Jeon BS. The G2019S LRRK2 mutation is rare in Korean patients with Parkinson's disease and multiple system atrophy. J Clin Neurol 2009;5:29-32.
28. Choi JM, Woo MS, Ma HI, Kang SY, Sung YH, Yong SW, et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 2008;9:263-9.
29. Fung HC, Chen CM, Hardy J, Hernandez D, Singleton A, Wu YR. Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease. Mov Disord 2006;21:880-1. (Pubitemid 44028316)
30. Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS, et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat Disord 2005;11:521-2. (Pubitemid 41627846)